A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

The company is poised to grow, even if it must shut down its compounded GLP-1 agonist business. The stock's valuation is jaw-droppingly cheap for what the business is already doing without GLP-1 ...

Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 -- the lowest average recorded in a ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

The GLP-1 agonists won’t be cheap any time soon as generic versions remain far in the future: The US patents for Ozempic and Wegovy won’t expire for another six or seven years. It is true that ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they really work? Zoë Beaty looks at how the health landscape is rapidly changing to ...

Their VK2735 drug is a GLP-1 dual agonist being developed for patients ... check out our report about the cheapest AI stock. Disclosure: None. Insider Monkey focuses on uncovering the best ...

Their VK2735 drug is a GLP-1 dual agonist being developed for patients ... check out our report about the cheapest AI stock.

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...